ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

Stroke · 2017 · PMC5404405 · PMID 28432265

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP =0.12not close (p > 0.1)

Secondary End Points At month 3, the mean ADAS-cog+ score had improved in both groups (−5.4 [0.53] for Actovegin and −4.3 [0.52] for placebo), but the LS mean treatment difference did not reach statistical significance (−1.1; 95% CI, −2.6, 0.3; P =0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.